Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Primary immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with low platelet
count. As the first choice of the second-line treatment of ITP, thrombopoietin receptor
agonist (TPO-RA) enable long-term remission in 50% to 60% of cases. However, about half of
patients have no response or loss of response due to unknown reasons, which can't be
effectively improved by increasing the drug dose. Diacerein is a slow-acting medicine of the
class anthraquinone used to treat joint diseases such as osteoarthritis. We speculate that
the addition of diacerein to eltrombopag may offer sensitizer effect and maximize efficacy,
and serve as an optimized second-line treatment for ITP patients.